Comparative Efficacy and Tolerability of No7 in Osteoarthritis of the Knee
Primary Purpose
Osteoarthritis, Knee
Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Solgar No7 Complex
placebo
Sponsored by
About this trial
This is an interventional supportive care trial for Osteoarthritis, Knee
Eligibility Criteria
Inclusion Criteria:
- Osteoarthritis (at least 2-nd grade according to Kellgren Classification)
- Ability to walk independently
- Pain Intensity of 4 or more according to Visual Analogue Scale
- NSAIDs usage of 5 times or more per month during 3 months before the intervention
- Ability to understand the benefits and risks of the proposed treatment and can provide answers to the required questions and fill out a questionnaire in Hebrew
- Early consent of participants not to start a new treatment for Osteoarthritis including medication, surgery, physiotherapy, laser therapy, etc. during the period of the study (3 months) - except for a clear medical need (should report to the investigators immediately)
Exclusion Criteria:
- Inflammatory Arthropathy, Severe Rheumatoid Arthritis, Psoriatic Arthritis or Gout
- History of injection of pharmacological material (steroids, anesthetic, hyaluronic acid or any other pharmacological substance) into the knee joint during the six months prior to the start of the study
- Taking of biological drugs that may affect inflammatory conditions (such as anti-TNF- alpha, etc.) or oral PO steroids - even if given to another disease, for more than 5 days during 3 months prior to the start of the study
- Chronic administration of any anti-inflammatory drug during the study period and / or at least one month prior to commencement of the study.
- Chronic administration of medical cannabis
- Use of analgetics in a formulation that provides a half-life of over 24 hours (eg, Butrans, Fentanyl)
- Chronic use of vitamin K antagonists, Heparin, Enoxaparin
- Injury to the knee during six months prior to the experiment
- Expectations of surgical intervention, physiotherapy or other treatment of osteoarthritis before the end of the study period
- Significant irregularities in renal or liver function, active malignant disease in the last 3 years, heart failure, uncontrolled hypertension, active peptic ulcer, hematologic diseases, severe neurological diseases, and mental illness with seizures in the last two years.
- Peripheral neuropathy that treated by any drug
- High alcohol consumption (over 2 standard doses per day)
- Sensitivity to one of the ingredients and / or sensitivity to NSAIDs. It is Possible to include a patient who is sensitive to a specific drug from the family of NSAIDs, but can take other drugs from this family.
- Any medical condition or treatment which, in the opinion of the investigators, may mask the results of the study and / or interfere with the research questions and / or terminate the research properly and / or endanger the participant in any way during the course of the study.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Solgar No7
Placebo for Solgar No7
Arm Description
Aflapin 100 mg and Collagen UC2 40 mg by mouth every 24 hours for 90 days
Placebo 1 Capsule by mouth, every 24 hours for 90 days
Outcomes
Primary Outcome Measures
Pain Intensity
Self reported pain intensity in the scale 1-10
Secondary Outcome Measures
Knee Stiffness
The stiffness of the knee according to the doctor evaluation
Non Steroidal Anti Inflammatory Drugs Usage
Self reported Non Steroidal Anti Inflammatory Drugs Usage
Adverse Reactions
Self reported Adverse Reactions
Full Information
NCT ID
NCT03442153
First Posted
January 9, 2018
Last Updated
February 20, 2018
Sponsor
Ambrosia - SupHerb Ltd.
1. Study Identification
Unique Protocol Identification Number
NCT03442153
Brief Title
Comparative Efficacy and Tolerability of No7 in Osteoarthritis of the Knee
Official Title
Comparative Efficacy and Tolerability of No7 in Osteoarthritis of the Knee: A Double Blind, Randomized, Placebo Controlled Clinical Study
Study Type
Interventional
2. Study Status
Record Verification Date
February 2018
Overall Recruitment Status
Unknown status
Study Start Date
March 2018 (Anticipated)
Primary Completion Date
May 2018 (Anticipated)
Study Completion Date
May 2018 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Ambrosia - SupHerb Ltd.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study evaluates the effect of dietary supplement Solgar No7 in 76 adult Osteoarthritis of the Knee Patients, while the other half will receive placebo.
Detailed Description
Solgar No7 is a Dietary Supplement marketed in Israel on a regular basis with the approval of the Israeli Ministry of Health. The product is based on Herbal Extracts and Vitamins. The individual components of the product were effective in some studies in relieving pain and inflammation in such patients. This Study evaluates the effect of these components as a complex.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis, Knee
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
The product in not drug or medical device (but a dietary supplement). There are 76 participants divided inti 2 groups : experimental group (38) and Placebo group (38). The period of the intervention: 90 days
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
76 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Solgar No7
Arm Type
Experimental
Arm Description
Aflapin 100 mg and Collagen UC2 40 mg by mouth every 24 hours for 90 days
Arm Title
Placebo for Solgar No7
Arm Type
Placebo Comparator
Arm Description
Placebo 1 Capsule by mouth, every 24 hours for 90 days
Intervention Type
Dietary Supplement
Intervention Name(s)
Solgar No7 Complex
Intervention Description
Solgar No7 Capsules
Intervention Type
Dietary Supplement
Intervention Name(s)
placebo
Other Intervention Name(s)
Placebo for Solgar No7
Intervention Description
Placebo tablets Cellulose
Primary Outcome Measure Information:
Title
Pain Intensity
Description
Self reported pain intensity in the scale 1-10
Time Frame
Pain intensity Reported to the Doctor after one month of the treatment. Each item is scored 0-10 (0=no pain; 10=pain as bad as can be), yielding a total between 0 and 30.
Secondary Outcome Measure Information:
Title
Knee Stiffness
Description
The stiffness of the knee according to the doctor evaluation
Time Frame
nee Stiffness checked by the Doctor after one month of treatment. Each item is scored 0-10 (0=no pain; 10=pain as bad as can be), yielding a total between 0 and 30
Title
Non Steroidal Anti Inflammatory Drugs Usage
Description
Self reported Non Steroidal Anti Inflammatory Drugs Usage
Time Frame
Pain Medication Usage as Reported to the Doctor after one month of treatment. Each item is scored as a number of the dose units that were used during the all period (0=no medications, 1=only one dose of medication etc)
Title
Adverse Reactions
Description
Self reported Adverse Reactions
Time Frame
Adverse Reactions as Reported to the Doctor over the period of the treatment. Each item is scored as a number of the dose units that were used during the all period (0=no adverse reactions, 1=only one adverse reaction etc)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
45 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Osteoarthritis (at least 2-nd grade according to Kellgren Classification)
Ability to walk independently
Pain Intensity of 4 or more according to Visual Analogue Scale
NSAIDs usage of 5 times or more per month during 3 months before the intervention
Ability to understand the benefits and risks of the proposed treatment and can provide answers to the required questions and fill out a questionnaire in Hebrew
Early consent of participants not to start a new treatment for Osteoarthritis including medication, surgery, physiotherapy, laser therapy, etc. during the period of the study (3 months) - except for a clear medical need (should report to the investigators immediately)
Exclusion Criteria:
Inflammatory Arthropathy, Severe Rheumatoid Arthritis, Psoriatic Arthritis or Gout
History of injection of pharmacological material (steroids, anesthetic, hyaluronic acid or any other pharmacological substance) into the knee joint during the six months prior to the start of the study
Taking of biological drugs that may affect inflammatory conditions (such as anti-TNF- alpha, etc.) or oral PO steroids - even if given to another disease, for more than 5 days during 3 months prior to the start of the study
Chronic administration of any anti-inflammatory drug during the study period and / or at least one month prior to commencement of the study.
Chronic administration of medical cannabis
Use of analgetics in a formulation that provides a half-life of over 24 hours (eg, Butrans, Fentanyl)
Chronic use of vitamin K antagonists, Heparin, Enoxaparin
Injury to the knee during six months prior to the experiment
Expectations of surgical intervention, physiotherapy or other treatment of osteoarthritis before the end of the study period
Significant irregularities in renal or liver function, active malignant disease in the last 3 years, heart failure, uncontrolled hypertension, active peptic ulcer, hematologic diseases, severe neurological diseases, and mental illness with seizures in the last two years.
Peripheral neuropathy that treated by any drug
High alcohol consumption (over 2 standard doses per day)
Sensitivity to one of the ingredients and / or sensitivity to NSAIDs. It is Possible to include a patient who is sensitive to a specific drug from the family of NSAIDs, but can take other drugs from this family.
Any medical condition or treatment which, in the opinion of the investigators, may mask the results of the study and / or interfere with the research questions and / or terminate the research properly and / or endanger the participant in any way during the course of the study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Evgeny Vaysberg, Pharmacist
Phone
+972506670597
Email
evgenyiw@solgar.co.il
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Guy Rubin
Organizational Affiliation
HaEmek Medical Center, Israel
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Comparative Efficacy and Tolerability of No7 in Osteoarthritis of the Knee
We'll reach out to this number within 24 hrs